Gilead operates a high-quality franchise with 43% return on equity, best-in-class margins of 31%, and a perfect four-quarter earnings beat streak, while 14.1% upside to the analyst consensus target and a 2.4-to-1 risk/reward offer a structurally sound setup. The near-term constraint is price momentum: the stock is below its 200-day moving average in what the data characterizes as a pullback within a still-rising trend—not a confirmed breakdown—but momentum has not yet turned to support a new commitment, and 90% of revenue concentrated in three wholesale distributors is a latent vulnerability.
Thesis pillars
- High Quality Franchise Best In Class Margins↓Deteriorating
- Consistent Earnings Delivery↓Deteriorating
- Momentum Headwind Not Confirmed Breakdown↑Improving
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 24, 2026· older than 90 days
Gilead Sciences, Inc. (GILD) Stock Analysis
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $174.48 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%).
Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35 countries, with more than 25 approved therapies in 2025. U.S. products are distributed primarily through three wholesalers—Cardinal Health, Cencora, and... Read more
Sell if holding. Analyst target reached at $174.48 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 4.8/10, high confidence.
Passes 6/7 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 96d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Gilead Sciences, Inc.
About Gilead Sciences, Inc.
Biktarvy, a once-daily single-tablet HIV regimen combining bictegravir, emtricitabine, and tenofovir alafenamide, holds U.S. patent protection through 2036 following settlement agreements signed in October 2025 with Lupin, Cipla, and Laurus Labs that preclude generic entry before April 1, 2036. Gilead Sciences' 2025 commercial portfolio exceeded 25 approved therapies spanning HIV, hepatitis B and C, oncology, and COVID-19, marketed across more than 35 countries. FDA also approved Yeztugo in 2025 as the first twice-yearly HIV PrEP capsid inhibitor available in the United States.
Gilead Sciences distributes products in the U.S. exclusively through the wholesale channel, with Cardinal Health, Cencora, and McKesson historically accounting for approximately 90% of U.S. gross product sales; for most HIV products the company uses multiple contract manufacturing organizations to maintain primary and back-up supply. HIV products represent a substantial portion of total revenue, and the company faces patent expirations across its portfolio — Trodelvy's U.S. compound patent expires in 2028 (regulatory exclusivity in 2032), and Tecartus' U.S. patent expires in 2027. Gilead also earns royalties and collaboration payments from arrangements with Merck, Arcellx, and Arcus Biosciences for pipeline programs including anitocabtagene autoleucel (in FDA review for multiple myeloma) and domvanalimab plus zimberelimab in Phase 3 for NSCLC.
Show full overview
In January 2026, the Department of Health and Human Services selected Biktarvy for Medicare price negotiation under the Inflation Reduction Act, with negotiated prices to take effect beginning in 2028. In December 2025, Gilead reached an agreement with the current U.S. Presidential administration to pause Section 232 tariffs for three years and implement most-favored-nation prices in Medicaid for select existing and future launched products. The 10-K notes that the full impact of these pricing mechanisms on revenue and Medicaid rebate obligations remains uncertain.
See also: Healthcare · Drug Manufacturers - General
From Gilead Sciences, Inc.'s most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated Nov 4, 2026Recent Developments — Gilead Sciences, Inc.
Latest news
- NEWS Gilead Sciences and Kite Announce Clinical Data Presentations for ASH 2026 — fiscal.ai Nov 4, 2026 neutral
- NEWS Gilead Sciences To Present 23 Presentations At 68th American Society of Hematology Annual Meeting — benzinga Nov 4, 2026 neutral
- NEWS Gilead Sciences (GILD) Prepares to Report Q3 Earnings Amid Mixed Growth and Valuation Concerns - GuruFocus — GuruFocus Oct 28, 2026 neutral
- NEWS Gilead Sciences earnings: what to look for from GILD - Yahoo Finance — Yahoo Finance Oct 28, 2026 neutral
- NEWS Gilead Sciences Q3 2026 Earnings Preview (GILD:NASDAQ) - Seeking Alpha — Seeking Alpha Oct 28, 2026 neutral
Latest item Nov 4, 2026 · Generated 2026-11-05T11:59:10Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHCustomerthree large wholesalers (Cardinal Health, Cencora, McKesson)90%10-K Item 1: 'approximately 90% of our gross product sales in the U.S. have been to three large wholesalers—Cardinal Health, Inc., Cencora, Inc. and McKesson Corporation'
- MEDIUMProductHIV products10-K Item 1A: 'We receive a substantial portion of our revenue from sales of our products for the treatment and prevention of HIV infection'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $174.48 — A.R:R is negative (-0.7) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $164.62. Score 4.8/10, high confidence.
Analyst target $155.25 reached (−11.0% from $174.48); no take-profit level is published. Prior stop was $164.62. Stop-loss: $164.62.
Concentration risk — Customer: three large wholesalers (Cardinal Health, Cencora, McKesson) (90.0%); Analyst target reached - limited upside remaining; Near 52-week high (0.7% away).
Gilead Sciences, Inc. trades at a P/E of N/A (forward 17.3). TrendMatrix value score: 4.4/10. Verdict: Sell.
36 analysts rate GILD, with a consensus score of 4.1/5. 26 analysts publish price targets averaging $173.
What does Gilead Sciences, Inc. do?Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35...
Gilead Sciences develops antiviral and oncology medicines across HIV, hepatitis, COVID-19, and cancer in more than 35 countries, with more than 25 approved therapies in 2025. U.S. products are distributed primarily through three wholesalers—Cardinal Health, Cencora, and McKesson—representing approximately 90% of U.S. gross product sales. HIV accounts for a substantial portion of total revenue; Biktarvy holds U.S. patent protection through 2036.